MicroPort’s Endovastec Delivers Double-Digit Top-Line and Bottom-Line Growth in Q1 2026

Bulletin Express04-29

Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (Endovastec), 40.32%-owned and consolidated by MicroPort Scientific Corporation, reported solid unaudited results for the three months ended 31 March 2026.

Revenue rose 11.45% year on year to RMB 370.24 million, up from RMB 332.19 million in the prior-year period, reflecting continued expansion of Endovastec’s endovascular product portfolio.

Profit increased 19.16% to RMB 179.77 million, while net profit attributable to equity owners advanced 19.44% to RMB 154.84 million, compared with RMB 150.87 million and RMB 129.64 million respectively in the first quarter of 2025.

As of 31 March 2026, total assets stood at RMB 4.79 billion, a 3.29% rise from the end-2025 level of RMB 4.64 billion. Total equity attributable to equity owners grew 3.50% over the same period to RMB 4.22 billion.

Management reiterated that these figures are prepared under PRC accounting standards, are unaudited, and cover only Endovastec, excluding other MicroPort subsidiaries and intra-group eliminations. The board cautioned shareholders and potential investors to exercise care when dealing in MicroPort securities.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1137467727?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-29 18:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1137467727","market":"us","top_or_hot":-1,"title":"MicroPort’s Endovastec Delivers Double-Digit Top-Line and Bottom-Line Growth in Q1 2026","media":"Bulletin Express","content":"<p>Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (Endovastec), 40.32%-owned and consolidated by MicroPort Scientific Corporation, reported solid unaudited results for the three months ended 31 March 2026.</p>\n<p>Revenue rose 11.45% year on year to RMB 370.24 million, up from RMB 332.19 million in the prior-year period, reflecting continued expansion of Endovastec’s endovascular product portfolio.</p>\n<p>Profit increased 19.16% to RMB 179.77 million, while net profit attributable to equity owners advanced 19.44% to RMB 154.84 million, compared with RMB 150.87 million and RMB 129.64 million respectively in the first quarter of 2025.</p>\n<p>As of 31 March 2026, total assets stood at RMB 4.79 billion, a 3.29% rise from the end-2025 level of RMB 4.64 billion. Total equity attributable to equity owners grew 3.50% over the same period to RMB 4.22 billion.</p>\n<p>Management reiterated that these figures are prepared under PRC accounting standards, are unaudited, and cover only Endovastec, excluding other MicroPort subsidiaries and intra-group eliminations. The board cautioned shareholders and potential investors to exercise care when dealing in MicroPort securities.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MicroPort’s Endovastec Delivers Double-Digit Top-Line and Bottom-Line Growth in Q1 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMicroPort’s Endovastec Delivers Double-Digit Top-Line and Bottom-Line Growth in Q1 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-29 18:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (Endovastec), 40.32%-owned and consolidated by MicroPort Scientific Corporation, reported solid unaudited results for the three months ended 31 March 2026.</p>\n<p>Revenue rose 11.45% year on year to RMB 370.24 million, up from RMB 332.19 million in the prior-year period, reflecting continued expansion of Endovastec’s endovascular product portfolio.</p>\n<p>Profit increased 19.16% to RMB 179.77 million, while net profit attributable to equity owners advanced 19.44% to RMB 154.84 million, compared with RMB 150.87 million and RMB 129.64 million respectively in the first quarter of 2025.</p>\n<p>As of 31 March 2026, total assets stood at RMB 4.79 billion, a 3.29% rise from the end-2025 level of RMB 4.64 billion. Total equity attributable to equity owners grew 3.50% over the same period to RMB 4.22 billion.</p>\n<p>Management reiterated that these figures are prepared under PRC accounting standards, are unaudited, and cover only Endovastec, excluding other MicroPort subsidiaries and intra-group eliminations. The board cautioned shareholders and potential investors to exercise care when dealing in MicroPort securities.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00853","symbol_name":"微创医疗","start_time":0,"source_url":"","article_id":"1137467727","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1137467727","pubTimestamp":1777459384,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (Endovastec), 40.32%-owned and consolidated by MicroPort Scientific Corporation, reported solid unaudited results for the three months ended...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"00853":"微创医疗"},"translate_title":"微创医疗Endovastec在2026年第一季度实现两位数的营收和利润增长","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00853":1},"content_text":"Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (Endovastec), 40.32%-owned and consolidated by MicroPort Scientific Corporation, reported solid unaudited results for the three months ended 31 March 2026.\nRevenue rose 11.45% year on year to RMB 370.24 million, up from RMB 332.19 million in the prior-year period, reflecting continued expansion of Endovastec’s endovascular product portfolio.\nProfit increased 19.16% to RMB 179.77 million, while net profit attributable to equity owners advanced 19.44% to RMB 154.84 million, compared with RMB 150.87 million and RMB 129.64 million respectively in the first quarter of 2025.\nAs of 31 March 2026, total assets stood at RMB 4.79 billion, a 3.29% rise from the end-2025 level of RMB 4.64 billion. Total equity attributable to equity owners grew 3.50% over the same period to RMB 4.22 billion.\nManagement reiterated that these figures are prepared under PRC accounting standards, are unaudited, and cover only Endovastec, excluding other MicroPort subsidiaries and intra-group eliminations. The board cautioned shareholders and potential investors to exercise care when dealing in MicroPort securities.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1137467727","isCrawlerRequest":true}